-+ 0.00%
-+ 0.00%
-+ 0.00%

ENDRA Life Sciences Q3 Net Loss Narrows to $1.53 Million

PUBT·11/16/2026 21:44:40
Listen to the news
ENDRA Life Sciences Q3 Net Loss Narrows to $1.53 Million
  • ENDRA Life Sciences’ third-quarter 2026 net loss narrowed to $1.53 million.
  • Operating expenses rose 25% year over year to $1.72 million, while research and development spending fell 59% to $176,280.
  • Cash used in operations increased 50% year over year to $1.8 million, primarily reflecting higher merger-related professional fees and digital-asset fees.
  • The proposed Noble Africa merger includes a concurrent private placement expected to raise approximately $50 million in gross proceeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611161644BIZWIRE_USPR_____20261116_BW500276) on November 16, 2026, and is solely responsible for the information contained therein.